Athenex announces completion of sale of dunkirk manufacturing facility

Buffalo, n.y., feb. 15, 2022 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the close of the sale of its leasehold interest in a manufacturing facility in dunkirk, new york, to immunitybio, inc. (nasdaq: ibrx), for approximately $40 million.
ATNX Ratings Summary
ATNX Quant Ranking